Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

benzinga.com/analyst-stock-ratings/downgrades/25/06/46034962/analyst-downgrades-sarepta-as-elevidys-safety-clouds-future-demand

Earlier this week, Sarepta Therapeutics, Inc (NASDAQ:SRPT) provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in…

This story appeared on benzinga.com, 2025-06-20 18:10:20.
The Entire Business World on a Single Page. Free to Use →